Kairos Pharma
KAPA
14 hedge funds and large institutions have $607K invested in Kairos Pharma in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
20% more capital invested
Capital invested by funds: $506K → $607K (+$102K)
1.96% more ownership
Funds ownership: 2.15% → 4.11% (+2%)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$301K |
| 2 |
Two Sigma Investments
New York
|
+$45.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$33.8K |
| 4 |
HF
HRT Financial
New York
|
+$20K |
| 5 |
VF
Virtu Financial
New York
|
+$19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$29.1K |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$27K |
| 3 |
QC
Quadrature Capital
London,
United Kingdom
|
-$17.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.62K |
KAPA Hedge Fund Activity: Q4 2025 in Review
14 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Kairos Pharma (KAPA) for Q4 2025, worth a combined $607K — up 20% from $506K a quarter earlier.
Fund positioning in KAPA was balanced in Q4 2025: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $301K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $29.1K sold.
- 14 institutional investors held Kairos Pharma (KAPA) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $607K of Kairos Pharma stock for Q4 2025, up 20% quarter-over-quarter.
- 5 funds opened new Kairos Pharma positions in Q4 2025 and 5 closed out, a net change of 0 holders.
- The largest Kairos Pharma buyer in Q4 2025 was Citadel Advisors, an estimated $301K added.
- The largest Kairos Pharma seller in Q4 2025 was Two Sigma Securities, an estimated $29.1K sold.
Based on aggregated 13F filings for Q4 2025.